Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

WHO revises treatment protocols for HIV patients

WHO revises treatment protocols for HIV patients

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

New HIV drug on the block

New HIV drug on the block

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Avexa halts HIV drug trials

Avexa halts HIV drug trials

Updates on development of Truvada and TMC278

Updates on development of Truvada and TMC278